Experimental prostate cancer vaccine trial halted early

NCT ID NCT05617040

Terminated Disease control Sponsor: Barinthus Biotherapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an experimental immunotherapy called VTP-850 in 22 men whose prostate cancer had returned (shown by rising PSA levels) after initial treatment like surgery or radiation. The therapy used two modified viruses to train the immune system to attack prostate cancer cells. The study was terminated early, so its full safety and effectiveness are unknown.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VTP-850 (a two-part vaccine using a chimpanzee adenovirus and a modified vaccinia virus to train the immune system against prostate cancer proteins)
What this could lead to: If it had succeeded, this could have pointed toward a new way to delay or avoid stronger treatments for men with early prostate cancer recurrence.
What could go wrong: The trial was terminated early, so results are limited. It was also a small, early-phase study, so even if completed, success was not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Carolina Urologic Research Center

Myrtle Beach, South Carolina, 29572, United States
Columbia University Irving Medical Center

New York, New York, 10032, United States
Cornell University

New York, New York, 10065-4805, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
University of Virginia Health System

Charlottesville, Virginia, 22908, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.